TriangleNCT00167219 · OUTCOME
Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- at 1 year after transplant
What was measured
Measured by AGVHD Grades 2 - 4.
Groups in this outcome
Intent-to-Treat
Patients receiving study regimen. Stem Cell Transplant: Transplantation on Day 0. Preparative Regimen: - Busulfan * Cyclophosphamide * Mesna * Melphalan * Anti-thymocyte Globulin (ATG)
| Group | Source count |
|---|---|
| Intent-to-Treat | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Intent-to-Treat | 33 | Not reported | 10 | 57 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 10
- upper Limit
- 57
- value
- 33
- denoms
- counts
- group Id
- OG000
- value
- 15
- units
- Participants
- description
- Measured by AGVHD Grades 2 - 4.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receiving study regimen. Stem Cell Transplant: Transplantation on Day 0. Preparative Regimen: - Busulfan * Cyclophosphamide * Mesna * Melphalan * Anti-thymocyte Globulin (ATG)
- id
- OG000
- title
- Intent-to-Treat
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- at 1 year after transplant
- title
- Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse.
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice